Keywords: بخش فعال سازی; AS; activation segment; CS or C-spine; catalytic spine; CL; catalytic loop; CTT; carboxyterminal tail; D1; immunoglobulin-like domain-1; EGFR; epidermal growth factor receptor; GIST; gastrointestinal stromal tumors; GK; gatekeeper; GRL; Gly-rich loop; KD;
مقالات ISI بخش فعال سازی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بخش فعال سازی; 7-Hydroxystaurosporine (PubMed CID: 72271); Abemaciclib (PubMed CID: 46220502); Alvocidib (PubMed CID: 5287969); AT7519 (PubMed CID: 11338033); BMS-387032 (PubMed CID: 3025986); Dinaciclib (PubMed CID: 46926350); Palbociclib (PubMed CID: 5330286); Ribocic
Keywords: بخش فعال سازی; Afatinib (PubMed CID: 10184653); Crizotinib (PubMed CID: 11626560); Erlotinib (PubMed CID: 176870); Gefitinib (PubMed CID: 123631); Imatinib (PubMed CID: 5291); Nilotinib (PubMed CID: 644241); Sorafinib (PubMed CID: 216239); Sunitinib (PubMed CID: 5329102
Keywords: بخش فعال سازی; AKAP; A-Kinase Anchoring Protein; ALL; acute lymphoblastic leukemia; A.S.; activation segment; CDK; cyclin-dependent kinase; CML; chronic myelogenous leukemia; C-spine; catalytic spine; EGFR; epidermal growth factor receptor; FGFR; fibroblast growth facto
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Keywords: بخش فعال سازی; ARTN; artemin; AS; activation segment; CD; cadherin-like domain; CDK; cyclin-dependent protein kinase; CL; catalytic loop; CS or C-spine; catalytic spine; CTT; carboxyterminal tail; EGFR; epidermal growth factor receptor; FGFR; fibroblast growth factor re
The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
Keywords: بخش فعال سازی; Axitinib: (PubMED CID: 6450551); Dasatinib: (PubMED CID: 3062316); Imatinib: (PubMED CID: 5291); Lenvatinib: (PubMED CID: 9823820); Nilotinib: (PubMed CID: 644241); Nintedanib: (PubMed CID: 9809715); Ponatinib: (PubMed CID: 24826799); Sorafenib: (PubMed C
Invited ReviewROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
Keywords: بخش فعال سازی; Cabozantinib (PubMED CID: 25102847); Ceritinib (PubMED CID: 57379345); Crizotinib (PubMED CID: 11626560); Entrectinib (PubMED CID: 25141092); Lorlatinib (PubMed CID: 71731823); AS; activation segment; CS or C-spine; catalytic spine; CL; catalytic loop; EG
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Keywords: بخش فعال سازی; Alectinib: (PubMED CID: 49806720); Brigatinib: (PubMED CID: 68165256); Ceritinib: (PubMED CID: 57379345); Crizotinib (PubMED CID: 11626560); Entrectinib: (PubMED CID: 25141092); Lorlatinib: (PubMed CID: 71731823); ALK+-NSCLC; ALK-positive non-small cell l
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
Keywords: بخش فعال سازی; AS; activation segment; CLL; chronic lymphocytic leukemia; CS or C-spine; catalytic spine; CL; catalytic loop; HΦ or Φ; hydrophobic; IP3; inositol 1,4,5 trisphosphate; IP6; inositol 1,2,3,4,5,6 hexakisphosphate; MCL; mantle cell lymphoma; MW; molecular
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Keywords: بخش فعال سازی; ALL; acute lymphocytic leukemia; AML; acute myelogenous leukemia; AS; activation segment; CS or C-spine; catalytic spine; CL; catalytic loop; HΦ or Φ; hydrophobic; IFN; interferon; IL; interleukin; JAK1/2; Janus kinases 1 and 2; MW; molecular weight; NS